ABBVCongressional Stock Trades
ABBVIE INC.
Pharmaceutical Preparations
Congressional stock trades in ABBVIE INC. (ABBV) from House and Senate STOCK Act filings. See which members of Congress bought or sold, disclosed amounts, and filing dates.
Total Trades
38
Politicians Trading
14
Last Traded
Sep 14, 2026
Trading History
| Politician | Notified | Traded | Type | Amount | Change |
|---|---|---|---|---|---|
| Ro KhannaD | Jul 6, 2026 | Jun 2, 2026 | Buy | $1,001 - $15,000 | +34.09% |
| Ro KhannaD | Jun 9, 2026 | May 15, 2026 | Buy | $15,001 - $50,000 | +37.29% |
| Ro KhannaD | Jun 9, 2026 | May 1, 2026 | Buy | $15,001 - $50,000 | +39.81% |
| Josh GottheimerD | Jun 3, 2026 | May 5, 2026 | Sell | $1,001 - $15,000 | +40.14% |
| Ro KhannaD | May 11, 2026 | Apr 13, 2026 | Sell | $15,001 - $50,000 | +39.89% |
| Julie JohnsonD | Jan 15, 2026 | Dec 18, 2025 | Sell | $1,001 - $15,000 | +29.63% |
| Julie JohnsonD | Dec 11, 2025 | Nov 13, 2025 | Sell | $1,001 - $15,000 | +24.34% |
| Julie JohnsonD | Sep 11, 2025 | Aug 14, 2025 | Sell | $1,001 - $15,000 | +41.12% |
| Ritchie TorresD | Aug 20, 2025 | Jul 11, 2025 | Sell | $1,001 - $15,000 | +50.09% |
| Josh GottheimerD | Jun 11, 2025 | May 22, 2025 | Buy | $1,001 - $15,000 | +58.23% |
| Josh GottheimerD | May 14, 2025 | Apr 17, 2025 | Sell | $1,001 - $15,000 | +66.97% |
| Josh GottheimerD | May 14, 2025 | Apr 3, 2025 | Buy | $1,001 - $15,000 | +43.25% |
| Josh GottheimerD | May 14, 2025 | Apr 1, 2025 | Buy | $1,001 - $15,000 | +40.03% |
| Jared MoskowitzD | May 9, 2025 | Apr 7, 2025 | Buy | $1,001 - $15,000 | +54.83% |
| Dwight EvansD | Apr 17, 2025 | Apr 3, 2025 | Sell | $1,001 - $15,000 | +43.25% |
| Jared MoskowitzD | Feb 10, 2025 | Jan 15, 2025 | Buy | $1,001 - $15,000 | +68.57% |
| Jared MoskowitzD | Feb 10, 2025 | Jan 15, 2025 | Buy | $1,001 - $15,000 | +68.57% |
Price History
About ABBVIE INC.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
14 members of Congress have disclosed 38 trades in ABBVIE INC. (ABBV). Most active: Lisa C. McClain (6), Josh Gottheimer (5), Ro Khanna (4).
Across all disclosures, members of Congress reported 20 purchases and 18 sales of ABBVIE INC. (ABBV). The most recent trade was on Sep 14, 2026.
Ro Khanna disclosed buying ABBVIE INC. (ABBV) on Jun 2, 2026, valued at $1,001 - $15,000.
Pete Sessions disclosed selling ABBVIE INC. (ABBV) on Sep 14, 2026, valued at $15,001 - $50,000.
From House and Senate periodic transaction reports filed under the STOCK Act. Members of Congress must disclose trades within 45 days, and amounts are reported as ranges, not exact values.